|
a. Multivariate cox regression analysis for parameters associated with all cause deaths
|
|
LVEF
|
1.060 [0.978–1.148]
|
0.157
|
0.994 [0.608–1.625]
|
0.981
|
|
6MWT
|
0.989 [0.974–1.003]
|
0.131
|
0.975 [0.869–1.093]
|
0.661
|
|
BNP
|
1.001 [0.999–1.020]
|
0.233
|
0.989 [0.963–1.016]
|
0.463
|
|
TNF alpha
|
1.666 [0.650–4.273]
|
0.288
|
2.253 [0.001–2.671]
|
0.939
|
|
GLP-1
|
2.980 [0.904–9.824]
|
0.073
|
5.127 [0.002–12.548]
|
0.445
|
|
CRP
|
0.977 [0.933–1.024]
|
0.336
|
0.867 [0.002–12.548]
|
0.548
|
|
IL-6
|
1.254 [0.811–1.939]
|
0.308
|
0.004 [0.545–1.380]
|
0.961
|
|
GLP-1 agonist
|
2.373 [1.087–5.182]
|
0.030
|
7.619 [0.004–14.031]
|
0.597
|
|
Age
|
1.140 [1.082–1.201]
|
0.001
|
1.063 [0.805–1.404]
|
0.665
|
|
Obesity
|
0.045 [0.001–2.916]
|
0.347
|
1.139 [0.001–3.434]
|
0.945
|
|
NYHA 3
|
1.518 [0.731–3.151]
|
0.263
|
0.037 [0.001–1.358]
|
0.273
|
|
COPD
|
3.793 [1.827–7.874]
|
0.001
|
0.107 [0.001–1.297]
|
0.529
|
|
QRS duration
|
1.005 [0.967–1.044]
|
0.810
|
0.981 [0.608–1.128]
|
0.081
|
|
Hypertension
|
1.686 [0.689–4.125]
|
0.252
|
0.005 [0.001–2.492]
|
0.087
|
|
Dyslipidemia
|
0.957 [0.391–2.341]
|
0.923
|
0.872 [0.401–4.951]
|
0.331
|
|
Renal dysfunction
|
1.054 [0.320–3.476]
|
0.931
|
3.854 [0.015–8.201]
|
0.095
|
|
Hb1Ac
|
0.756 [0.435–1.347]
|
0.354
|
0.416 [0.072–2.415]
|
0.328
|
|
b. Multivariate cox regression analysis for parameters associated with cardiac deaths
|
|
LVEF
|
0.952 [0.902–1.006]
|
0.080
|
0.438 [0.001–8.345]
|
0.831
|
|
6MWT
|
0.998 [0.987–1.009]
|
0.733
|
1.141 [0.778–1.673]
|
0.510
|
|
BNP
|
1.001 [0.989–1.010]
|
0.853
|
0.993 [0.935–1.054]
|
0.831
|
|
TNF alpha
|
2.277 [1.091–4.752]
|
0.028
|
0.201 [0.011–8.955]
|
0.727
|
|
GLP-1
|
2.980 [0.904–9.824]
|
0.073
|
5.127 [0.002–12.548]
|
0.445
|
|
CRP
|
0.961 [0.920–1.004]
|
0.075
|
4.282 [0.035–5.287]
|
0.554
|
|
IL-6
|
1.364 [0.976–1.906]
|
0.069
|
7.623 [0.002–12.782]
|
0.724
|
|
GLP-1 agonist
|
1.691 [0.929–3.087]
|
0.085
|
0.001 [0.015–1.491]
|
0.687
|
|
Age
|
1.307 [1.237–1.381]
|
0.001
|
2.680 [0.562–12.791]
|
0.095
|
|
Obesity
|
1.018 [0.316–3.282]
|
0.976
|
0.013 [0.005–6.410]
|
0.772
|
|
NYHA 3
|
8.791 [3.474–22.248]
|
0.001
|
0.010 [0.001–7.279
|
0.633
|
|
COPD
|
2.041 [1.143–3.646]
|
0.016
|
0.421 [0.001–1.760]
|
0.863
|
|
QRS duration
|
0.990 [0.959–1.021]
|
0.528
|
2.797 [0.333–23.510]
|
0.344
|
|
Hypertension
|
1.744 [0.842–3.614]
|
0.135
|
0.031 [0.001–2.310]
|
0.868
|
|
Dyslipidemia
|
3.473 [1.078–11.195]
|
0.037
|
4.939 [0.001–12.181]
|
0.358
|
|
Renal dysfunction
|
0.636 [0.197–2.051]
|
0.449
|
0.052 [0.003–1.193]
|
0.422
|
|
Hb1Ac
|
1.429 [0.911–2.241]
|
0.120
|
3.119 [0.384–4.091]
|
0.167
|
|
c. Multivariate cox regression analysis for parameters associated with hospitalization for heart failure
|
|
LVEF
|
0.978 [0.945–1.012]
|
0.199
|
0.927 [0.826–1.041]
|
0.202
|
|
6MWT
|
1.003 [0.997–1.010]
|
0.301
|
1.013 [0.992–1.034]
|
0.226
|
|
BNP
|
1.002 [1.001–1.020]
|
0.001
|
1.120 [1.001–1.401]
|
0.017*
|
|
TNF alpha
|
1.078 [0.665–1.749]
|
0.761
|
0.028 [0.000–1.673]
|
0.420
|
|
GLP-1
|
1.719 [1.077–2.744]
|
0.023
|
1.143 [0.451–2.900]
|
0.778
|
|
CRP
|
0.987 [0.967–1.007]
|
0.207
|
0.981 [0.923–1.042]
|
0.530
|
|
IL-6
|
1.163 [0.926–1.460]
|
0.193
|
1.879 [0.017–2.129]
|
0.272
|
|
GLP-1 agonist
|
1.914 [1.335–2.744]
|
0.001
|
0.119 [0.028–0.508]
|
0.004*
|
|
Age
|
1.005 [0.979–1.033]
|
0.691
|
0.977 [0.891–1.072]
|
0.624
|
|
Obesity
|
0.997 [0.488–2.039]
|
0.994
|
0.923 [0.826–1.742]
|
0.983
|
|
NYHA 3
|
1.680 [1.177–2.397]
|
0.004
|
1.43 [0.398–1.041]
|
0.562
|
|
COPD
|
1.126 [0.776–1.633]
|
0.533
|
6.870 [0.639–7.383]
|
0.112
|
|
QRS duration
|
1.005 [0.987–1.024]
|
0.578
|
1.031 [0.963–1.102]
|
0.383
|
|
Hypertension
|
0.875 [0.606–1.265]
|
0.478
|
1.381 [0.342–5.583]
|
0.651
|
|
Dyslipidemia
|
1.932 [1.128–3.311]
|
0.016
|
0.354 [0.081–1.541]
|
0.166
|
|
Renal dysfunction
|
0.889 [0.479–1.649]
|
0.709
|
0.565 [0.103–3.098]
|
0.510
|
|
Hb1Ac
|
1.255 [0.955–1.649]
|
0.103
|
0.967 [0.626–1.493]
|
0.879
|
|
d. Multivariate cox regression analysis for parameters associated with CRT responders
|
|
LVEF
|
1.043 [1.019–1.068]
|
0.001
|
1.032 [0.979–1.089]
|
0.239
|
|
6MWT
|
1.010 [0.996–1.410]
|
0.897
|
0.998 [0.987–1.008]
|
0.665
|
|
BNP
|
1.001 [0.989–1.001]
|
0.487
|
1.012 [0.989–1.189]
|
0.962
|
|
TNF alpha
|
0.950 [0.688–1.312]
|
0.755
|
0.508 [0.007–3.712]
|
0.757
|
|
GLP-1
|
0.840 [0.660–1.069]
|
0.156
|
0.757 [0.510–1.123]
|
0.166
|
|
CRP
|
0.997 [0.986–1.008]
|
0.601
|
0.997 [0.966–1.029]
|
0.851
|
|
IL-6
|
1.007 [0.857–1.183]
|
0.930
|
0.823 [0.010–6.662]
|
0.953
|
|
GLP-1 agonist
|
1.041 [0.841–1.288]
|
0.714
|
3.707 [1.226–14.570]
|
0.026*
|
|
Age
|
0.988 [0.972–1.005]
|
0.154
|
1.010 [0.957–1.045]
|
0.992
|
|
Obesity
|
1.394 [0.934–2.080]
|
0.104
|
0.564 [0.192–1.656]
|
0.297
|
|
NYHA 3
|
0.711 [0.573–0.881]
|
0.020
|
1.222 [0.646–2.313]
|
0.538
|
|
COPD
|
0.796 [0.624–1.015]
|
0.066
|
2.474 [0.965–6.343]
|
0.059
|
|
QRS duration
|
0.989 [0.978–1.001]
|
0.053
|
0.999 [0.971–1.027]
|
0.059
|
|
Hypertension
|
1.073 [0.850–1.355]
|
0.554
|
0.774 [0.430–1.394]
|
0.394
|
|
Dyslipidemia
|
0.848 [0.653–1.102]
|
0.218
|
1.135 [0.632–2.039]
|
0.671
|
|
Renal dysfunction
|
0.937 [0.651–1.349]
|
0.727
|
1.685 [0.666–4.260]
|
0.270
|
|
Hb1Ac
|
1.028 [0.864–1.222]
|
0.756
|
1.170 [0.949–1.442]
|
0.141
|
|
e. Multivariate cox regression analysis for parameters associated with strokes
|
|
LVEF
|
0.931 [0.866–1.002]
|
0.055
|
0.449 [0.033–7.319]
|
0.758
|
|
6MWT
|
0.989 [0.973–1.006]
|
0.203
|
1.065 [0.232–4.894]
|
0.935
|
|
BNP
|
1.001 [0.989–1.020]
|
0.297
|
0.991 [0.809–1.214]
|
0.932
|
|
TNF alpha
|
1.062 [0.347–3.250]
|
0.917
|
0.016 [0.001–6.694]
|
0.988
|
|
GLP-1
|
2.315 [0.69–7.761]
|
0.174
|
0.020 [0.001–7.072]
|
0.862
|
|
CRP
|
0.983 [0.935–1.033]
|
0.502
|
1.215 [0.002–7.735]
|
0.953
|
|
IL-6
|
0.617 [0.273–1.394]
|
0.245
|
2.159 [0.001–3.829]
|
0.991
|
|
GLP-1 agonist
|
1.691 [0.740–3.864]
|
0.213
|
1.320 [0.001–6.473]
|
0.913
|
|
Age
|
0.946 [0.885–1.012]
|
0.104
|
1.263 [0.004–4.136]
|
0.937
|
|
Obesity
|
5.241 [2.080–13.205]
|
0.001
|
0.031 [0.001–2.678]
|
0.771
|
|
NYHA 3
|
0.994 [0.447–2.213]
|
0.989
|
0.129 [0.001–5.426]
|
0.960
|
|
COPD
|
1.764 [0.784–3.972]
|
0.170
|
0.212 [0.001–1.878]
|
0.896
|
|
QRS duration
|
1.001 [0.960–1.045]
|
0.951
|
1.315 [0.059–2.940]
|
0.960
|
|
Hypertension
|
1.264 [0.502–3.185]
|
0.619
|
2.066 [0.001–11.954]
|
0.982
|
|
Dyslipidemia
|
0.699 [0.277–1.762]
|
0.448
|
0.948 [0.001–3.020]
|
0.794
|
|
Renal dysfunction
|
0.043 [0.001–16.543]
|
0.301
|
0.880 [0.001–1.003]
|
0.880
|
|
Hb1Ac
|
1.115 [0.412–3.021]
|
0.830
|
4.248 [0.001–5.346]
|
0.752
|
|
f. Multivariate cox regression analysis for parameters associated with VT events
|
|
LVEF
|
1.041 [0.985–1.100]
|
0.157
|
1.160 [1.012–1.290]
|
0.047*
|
|
6MWT
|
0.993 [0.983–1.040]
|
0.203
|
0.993 [0.983–1.004]
|
0.194
|
|
BNP
|
1.001 [0.909–1.020]
|
0.321
|
1.001 [0.098–1.002]
|
0.505
|
|
TNF alpha
|
1.475 [0.749–2.904]
|
0.261
|
1.009 [0.484–2.101]
|
0.981
|
|
GLP-1
|
1.839 [0.904–3.739]
|
0.093
|
0.878 [0.585–1.317]
|
0.529
|
|
CRP
|
0.973 [0.940–1.007]
|
0.121
|
0.991 [0.958–1.025]
|
0.609
|
|
IL-6
|
1.384 [1.034–1.853]
|
0.029
|
1.076 [0.780–1.485]
|
0.654
|
|
GLP-1 agonist
|
0.332 [0.185–0.597]
|
0.001
|
0.964 [0.963–0.992]
|
0.012*
|
|
Age
|
1.039 [1.001–1.079]
|
0.046
|
1.051 [0.816–1.599]
|
0.066
|
|
Obesity
|
5.478 [3.005–9.987]
|
0.001
|
0.174 [0.016–1.599]
|
0.072
|
|
NYHA 3
|
2.773 [1.562–4.923]
|
0.001
|
0.541 [0.281–1.043]
|
0.067
|
|
COPD
|
2.345 [1.404–3.915]
|
0.001
|
0.846 [0.466–1.538]
|
0.584
|
|
QRS duration
|
0.975 [0.948–1.003]
|
0.080
|
1.511 [1.160–1.959]
|
0.026*
|
|
Hypertension
|
0.805 [0.469–1.380]
|
0.430
|
1.031 [0.570–1.863]
|
0.920
|
|
Dyslipidemia
|
2.619 [1.048–6.548]
|
0.039
|
1.232 [0.715–2.122]
|
0.452
|
|
Renal dysfunction
|
1.056 [0.454–2.456]
|
0.901
|
0.420 [0.012–1.531]
|
0.075
|
|
Hb1Ac
|
1.239 [0.760–2.020]
|
0.389
|
1.320 [0.021–3.426]
|
0.752
|
|
g. Multivariate cox regression analysis for parameters associated with AF events
|
|
LVEF
|
0.964 [0.934–0.994]
|
0.021
|
1.593 [1.122–1.986]
|
0.006*
|
|
6MWT
|
1.001 [0.994–1.601]
|
0.977
|
1.024 [0.995–1.046]
|
0.712
|
|
BNP
|
1.020 [1.001–1.100]
|
0.008
|
1.101 [1.001–1.210]
|
0.017*
|
|
TNF alpha
|
1.180 [0.759–1.836]
|
0.462
|
1.298 [0.773–2.180]
|
0.324
|
|
GLP-1
|
1.049 [0.720–1.526]
|
0.804
|
1.087 [0.829–1.427]
|
0.962
|
|
CRP
|
1.010 [0.983–1.180]
|
0.561
|
0.997 [0.979–1.015]
|
0.732
|
|
IL-6
|
1.016 [0.808–1.277]
|
0.983
|
0.936 [0.703–1.247]
|
0.652
|
|
GLP-1 agonist
|
0.577 [0.348–0.957]
|
0.033
|
0.603 [0.411–0.884]
|
0.010*
|
|
Age
|
0.989 [0.964–1.014]
|
0.388
|
0.982 [0.957–1.008]
|
0.182
|
|
Obesity
|
0.941 [0.479–1.846]
|
0.859
|
0.952 [0.493–1.841]
|
0.885
|
|
NYHA 3
|
1.044 [0.756–1.441]
|
0.795
|
0.942 [0.670–1.324]
|
0.730
|
|
COPD
|
1.113 [0.785–1.577]
|
0.548
|
1.020 [0.683–1.523]
|
0.924
|
|
QRS duration
|
1.020 [1.003–1.037]
|
0.020
|
1.182 [1.012–1.552]
|
0.043*
|
|
Hypertension
|
0.929 [0.656–1.316]
|
0.680
|
1.519 [0.926–2.492]
|
0.098
|
|
Dyslipidemia
|
0.828 [0.560–1.223]
|
0.343
|
1.232 [0.715–2.122]
|
0.452
|
|
Renal dysfunction
|
0.588 [0.598–1.162]
|
0.126
|
0.613 [0.024–1.618]
|
0.082
|
|
Hb1Ac
|
1.176 [0.914–1.512]
|
0.208
|
1.150 [0.002–2.152]
|
0.073
|
